Effects of Pelargonium sidoides extract EPs 7630 on acute cough and quality of life – a meta-analysis of randomized, placebo-controlled trials
Keywords:
Acute bronchitis, acute cough, acute respiratory tract infection, common cold, EPs 7630, meta-analysis, Pelargonium, quality of lifeAbstract
Background: Cough is a leading symptom of viral acute respiratory infections such as acute bronchitis (AB) and the common cold (CC), which can be debilitating and may persist for several weeks. We investigated whether treatment with Pelargonium extract EPs 7630 may reduce cough and improve disease-related quality of life (QoL).
Methods: We performed a meta-analysis of randomized, placebo-controlled trials investigating the efficacy of EPs 7630 in AB or CC. Efficacy analyses included change from baseline in a cough intensity score, remission of cough, and disease-associated impairments of QoL.
Results: Data of 2,195 participants from 11 trials (3 in children/adolescents with AB, 3 in adults with AB, 5 in adults with CC) were eligible. In children/adolescents with AB, 79.6% of participants treated with EPs 7630 and 41% treated with placebo showed a reduction in intensity of cough by at least 50% of baseline values at day 7 [meta-analysis rate/risk ratio (RR), EPs 7630 / placebo: 1.86 (95% CI: 1.34; 2.95)], and 18.0% vs 5.5% presented with complete remission of cough [RR: 2.91 )95% CI: 1.26; 6.72)]. In adults with AB, 88.7% of participants in the EPs 7630 group and 47.6% in the placebo group showed a ≥50% response for cough intensity [RR: 2.13 (95% CI: 1.37; 3.31)], while 26.0% vs 6.3% did not cough any more at day 7 [RR: 5.00 [95% CI: 3.10; 8.07)]. Cough scale results were supported by significant improvements over placebo in the pursuit of normal daily activities and other QoL measures. In CC, 56.8% of participants treated with EPs 7630 and 38.8% treated with placebo showed a ≥50% cough intensity reduction [RR: 1.40 (95% CI: 1.19; 1.65)] at day 5, while 26.1% versus 18.4% showed complete remission of cough for EPs 7630 and placebo, respectively [RR: 1.40 (95% CI: 1.06; 1.84)]. CC-associated pain/discomfort and an impairment of usual activities were no longer present in 41.5% and 48.8% of participants treated with EPs 7630 compared to less than 40% of patients in the placebo group.
Conclusions: The results show that EPs 7630 reduces the burden and leads to earlier remission of cough. Advantages for EPs 7630 were also reflected in self-rated measures of disease-associated QoL. Of note, patients treated with the herbal product felt able to resume their usual daily activities sooner.
References
File TM. The epidemiology of respiratory tract infections. Semin Respir Infect 2000;15:184-94.
Monto AS, Malosh RE, Petrie JG, Thompson MG, Ohmit SE. Frequency of acute respiratory illnesses and circulation of respiratory viruses in households with children over 3 surveillance seasons. J Infect Dis 2014;210:1792-9.
Renati S, Linder JA. Necessity of office visits for acute respiratory infections in primary care. Fam Pract 2016;33:312-7.
Kardos P, Dinh QT, Fuchs KH, Gillissen A, Klimek L, Koehler M, et al. [Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von erwachsenen Patienten mit Husten].[Article in German with English abstract]. Pneumologie 2019;73:143-80.
Marchant JM, Newcombe PA, Juniper EF, Sheffield JK, Stathis SL, Chang AB. What is the burden of chronic cough for families? Chest 2008;134:303-9.
Morice A, Kardos P. Comprehensive evidence-based review on European antitussives. BMJ Open Respir Res 2016;3:e000137.
Finley CR, Chan DS, Garrison S, Korownyk C, Kolber MR, Campbell S, et al. What are the most common conditions in primary care? Systematic review. Can Fam Physician 2018;64:832-40.
Footitt J, Johnston SL. Cough and viruses in airways disease: mechanisms. Pulm Pharmacol Ther 2009;22:108-13.
Dicpinigaitis PV. Effect of viral upper respiratory tract infection on cough reflex sensitivity. J Thorac Dis 2014;6:S708-S11.
Thomas M, Koutsothanasis GA, Bomar PA. Upper respiratory tract infection. Treasure Island: StatPearls Publishing; 2020.
DeGeorge KC, Ring DJ, Dalrymple SN. Treatment of the common cold. Am Fam Physician 2019;100:281-9.
Iwata T, Ito I, Niimi A, Ikegami K, Marumo S, Tanabe N, et al. Mechanical stimulation by postnasal drip evokes cough. PLoS One 2015;10:e0141823.
Yu JL, Becker SS. Postnasal drip and postnasal drip-related cough. Curr Opin Otolaryngol Head Neck Surg 2016;24:15-9.
Kardos P, Malek FA. Common cold – an umbrella term for acute infections of nose, throat, larynx and bronchi. Pneumologie 2017;71:221-6.
Morice AH, Kantar A, Dicpinigaitis PV, Birring SS, McGarvey LP, Chung KF. Treating acute cough: wet versus dry – have we got the paradigm wrong? ERJ Open Res 2015;1:00055-2015.
Hordijk PM, Broekhuizen BDL, Butler CC, Coenen S, Godycki-Cwirko M, Goossens H, et al. Illness perception and related behaviour in lower respiratory tract infections - a European study. Fam Pract 2015;32:152-8.
Lovie-Toon YG, Chang AB, Newcombe PA, Vagenas D, Anderson-James S, Drescher BJ, et al. Longitudinal study of quality of life among children with acute respiratory infection and cough. Qual Life Res 2018;27:891-903.
Mahowald M, Shahan B, Forbes D. Respiratory conditions: lower respiratory tract infections. FP Essent 2019;486:19-25.
Wang DY, Eccles R, Bell J, Chua AH, Salvi S, Schellack N, et al. Management of acute upper respiratory tract infection: the role of early intervention. Expert Rev Respir Med 2021;15:1517-23.
Reynolds SM, Mackenzie AJ, Spina D, Page CP. The pharmacology of cough. Trends Pharmacol Sci 2004;25:569-76.
Schönknecht K, Fal AM, Mastalerz-Migas A, Joachimiak M, Doniec Z. Efficacy of dry extract of ivy leaves in the treatment of productive cough. Wiad Lek 2017;70:1026-33.
Moyo M, Van Staden J. Medicinal properties and conservation of Pelargonium sidoides DC. J Ethnopharmacol 2014;152:243-55.
Careddu D, Pettenazzo A. Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children. Int J Gen Med 2018;11:91-8.
Michaelis M, Doerr HW, Cinatl J, Jr. Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. Phytomedicine 2011;18:384-6.
Keck T, Strobl A, Weinhaeusel A, Funk P, Michaelis M. Pelargonium extract EPs 7630 in the treatment of human Corona virus-associated acute respiratory tract infections – A secondary subgroup-analysis of an open-label, uncontrolled clinical trial. Front Pharmacol 2021;12:666546.
Roth M, Fang L, Stolz D, Tamm M. Pelargonium sidoides radix extract EPs 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells. PLoS One 2019;14:e0210702.
Bao Y, Gao Y, Koch E, Pan X, Jin Y, Cui X. Evaluation of pharmacodynamic activities of EPs(R) 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis. Phytomedicine 2015;22:504-9.
Papies J, Emanuel J, Heinemann N, Kulić Ž, Schroeder S, Tenner B, et al. Antiviral and immunomodulatory effects of Pelargonium sidoides DC. root extract EPs® 7630 in SARS-CoV-2-infected human lung cells. Front Pharmacol 2021;12:757666.
Agbabiaka TB, Guo R, Ernst E. Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis. Phytomedicine 2008;15:378-85.
Ulbricht C, Abrams TR, Conquer J, Costa D, Serrano JM, Iovin R, et al. An evidence-based systematic review of umckaloabo (Pelargonium sidoides) by the Natural Standard Research Collaboration. J Diet Suppl 2010;7:283-302.
Timmer A, Günther J, Motschall E, Rücker G, Antes G, Kern WV. Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev 2013(10):CD006323.
Wagner L, Cramer H, Klose P, Lauche R, Gass F, Dobos G, et al. Herbal medicine for cough: a systematic review and meta-analysis. Forsch Komplementmed 2015;22:359-68.
Matthys H, Lehmacher W, Zimmermann A, Brandes J, Kamin W. EPs 7630 in acute respiratory tract infections – a systematic review and meta-analysis of randomized clinical trials. J Lung Pulm Respir Res 2016;3:4-15.
Kamin W, Funk P, Seifert G, Zimmermann A, Lehmacher W. EPs 7630 is effective and safe in children under 6 years with acute respiratory tract infections: clinical studies revisited. Curr Med Res Opin 2018;34:475-85.
Schapowal A, Dobos G, Cramer H, Ong KC, Adler M, Zimmermann A, et al. Treatment of signs and symptoms of the common cold using EPs 7630 - results of a meta-analysis. Heliyon 2019;5:e02904.
Matthys H, Köhler S, Kamin W. Safety and tolerability of EPs 7630 in clinical trials. Adv Pharmacoepidemiol Drug Saf 2013;2:142.
The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
Heger M, Bereznoy VV. [Tonsillopharyngitis in children not caused by streptococci: Efficacy of an extract from Pelargonium sidoides (EPs 7630) in comparison with placebo]. In: Schulz V, Rietbrock N, Roots I, Loew D, editors. [Phytopharmaka in Forschung und klinischer Anwendung].[Book in German]. Vol. VII. Darmstadt: Steinkopff; 2002. p. 13-25.
Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med 2017;36:855-75.
Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. 2020. In: Cochrane Handbook for Systematic Reviews of Interventions version 61 (updated September 2020) [Internet]. The Cochrane Collaboration. Available from: www.training.cochrane.org/handbook
Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane; 2022. Available from: www.training.cochrane.org/handbook
Review Manager (RevMan). Version 5.2 [Computer Program]. The Cochrane Collaboration; 2012.
Kamin W, Maydannik V, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis - a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots. Int J Clin Pharmacol Ther 2010;48:184-91.
Kamin W, Maydannik VG, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis - A randomized, double-blind, placebo-controlled clinical dose-finding study. Acta Paediatr 2010;99:537-43.
Kamin W, Ilyenko LI, Malek FA, Kieser M. Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. Pediatr Int 2012;54:219-26.
Chuchalin AG, Berman B, Lehmacher W. Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs® 7630): a randomized, double-blind, placebo-controlled trial. Explore 2005;1:437-45.
Matthys H, Heger M. Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study. Curr Med Res Opin 2007;23:323-31.
Matthys H, Lizogub VG, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides. Curr Med Res Opin 2010;26:1413-22.
Lizogub VG, Riley DS, Heger M. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial. Explore (NY) 2007;3:573-84.
Riley DS, Lizogub VG, Zimmermann A, Funk P, Lehmacher W. Efficacy and tolerability of high-dose Pelargonium extract in patients with the common cold. Altern Ther Health Med 2018;24:16-26.
Riley DS, Lizogub VG, Heger M, Funk P, Müller H, Lehmacher W. Treatment with EPs 7630, a Pelargonium sidoides root extract, is effective and safe in patients with the common cold: results from a randomized, double blind, placebo-controlled clinical trial. Integr Med (Encinitas) 2019;18:42-51.
Ebell MH, Lundgren J, Youngpairoj S. How long does a cough last? Comparing patients' expectations with data from a systematic review of the literature. Ann Fam Med 2013;11:5-13.
Lehrl S, Matthys H, Kamin W, Kardos P. The BSS - A valid clinical instrument to measure the severity of acute bronchitis. J Lung Pulm Respir Res 2014;1:72-80.
Lehrl S, Kardos P, Matthys H, Kamin W. Validation of a clinical instrument for measuring the severity of acute bronchitis in children - the BSS-ped. Open Respir Med J 2018;12:50-66.
Längler A, Zuzak TJ, Fricke O, Seifert G. [Pflanzliche Arzneimittel in der Pädiatrie].[Article in German with English abstract]. Monatsschrift Kinderheilkunde 2019;167:768-77.
Published
Issue
Section
License
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
